Blood Pressure Treatment and Biomarker Outcomes for Alzheimer Disease: How Low Should You Go?

Results are inconclusive on the effects of intensive versus standard blood pressure control on the progression of AD-related MRI brain outcomes.

Hypertension is a risk factor for dementia. Researchers conducting this substudy from the Systolic Blood Pressure Intervention Trial (SPRINT MIND) compared the efficacy of intensive versus standard blood pressure lowering on MRI brain biomarkers for Alzheimer disease (AD) in dementia-free participants >50 years with systolic blood pressure (SBP) between 130 and 180 mm Hg. Goal SBP was <120 mm Hg in the intensive treatment (n=356) and <140 mm Hg with standard treatment (n=317). At baseline (mean age, 67 years; 32% Black; mean BP, 138.78) and 4-year follow-up, AD-related findings were measured, including cognitive performance and several brain MRI–based findings: longitudinal hippocampal volumes, cortical thickness, spatial pattern for the re…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Blood Pressure Treatment and Biomarker Outcomes for Alzheimer Disease: How Low Should You Go?

Topics

Reviewing Author